Post a Comment Print Share on Facebook
Featured Audiencia Nacional PSOE Feijóo Irán CNMV

RELEASE: Seegene announces its collaboration with Microsoft to make "a disease-free world" a reality

(Information sent by the signatory company).

- 2 reads.

RELEASE: Seegene announces its collaboration with Microsoft to make "a disease-free world" a reality

(Information sent by the signatory company)

SEOUL, South Korea, January 29, 2024 /PRNewswire/ -- Seegene Inc. (KQ096530), a leading South Korean company in comprehensive solutions for molecular diagnostics by PCR, announced on January 23 in London, United Kingdom, the selection of Microsoft as a technology partner for its SG OneSystemTM project, aiming to make "a disease-free world" a reality.

Seegene will collaborate with Microsoft to help drive the growth of its SG OneSystemTM business, an unprecedented strategy by Seegene to share its unique syndromic quantitative PCR technologies with leading companies around the world, to drive cross-sector innovation in molecular diagnostics. The expansion of participating companies, with which Seegene aims to form a global consortium, will equip countries around the world with optimal solutions, allowing them to effectively confront future pandemics and collectively move closer to "a disease-free world." .

To realize this goal, Seegene will work with Microsoft's global healthcare team by helping to drive the growth of SG OneSystemTM, championing the collective vision, building bridges between potential partners and jointly participating in the annual SG OneSystemTM symposium. Other key events to connect current and potential SG OneSystemTM partners will be held in the first half of this year, including a ceremony to communicate the new vision to scientific communities and other partners involved in the SG OneSystemTM business.

The Seegene Digital Development System (SGDDS) will integrate Microsoft Azure services, including Azure OpenAI Service, which will be used by Seegene to facilitate data interaction and analysis for researchers dealing with extensive data generated by the SGDDS. Deploying the highly secure and compliant Azure Trusted Research Environment (TRE) will push the boundaries of PCR research, helping to ensure both privacy and regulatory compliance. Seegene will deploy Microsoft Fabric, a single AI-powered analytics platform that will unify Seegene data and reshape how everyone accesses, manages and acts on that data, with capabilities spanning data integration, data engineering, science data management, data monitoring, real-time analytics and business intelligence. The integration of AI-powered assistance through Copilot for Microsoft 365 is expected to accelerate productivity, foster innovation, and enhance creativity.

Additionally, Seegene will collaborate with Microsoft on collective healthcare innovation research, including management and analysis of the next generation of PCR data, and explore future projects in the healthcare sector. Seegene and Microsoft's goal is to improve the healthcare ecosystem by providing early and accurate disease diagnoses, which lay the foundation for effective treatment and prevention.

"The strategic collaboration with Microsoft will allow us to have a more structured SG OneSystemTM business model," explained Dr. Jong-Yoon Chun, CEO and founder of Seegene. "Through our joint efforts, we hope that synergistic effects will pave the way toward a disease-free world."

"We support Seegene's vision of making 'a disease-free world' a reality," said Elena Bonfiglioli, general manager of Global Health and Life Sciences at Microsoft. "In addition to working with Seegene on their digital transformation, we will collaborate to attract new global partners and further improve the healthcare ecosystem."

About Seegene

Seegene has 23 years of experience dedicated to the R&D, manufacturing and business of syndromic quantitative PCR technologies, which was evident during the COVID-19 pandemic when it supplied more than 340 million COVID-19 tests. to more than 100 countries around the world. The key feature of syndromic PCR technologies, unique to Seegene, is the ability to simultaneously analyze 14 pathogens causing similar symptoms in a single tube and provide quantitative information on the infectivity profile to correlate with disease severity.

SG OneSystem TM Project

The SG OneSystemTM Project is a global strategy to realize "a disease-free world." The goal of SG OneSystemTM is to enable scientists and experts to locally develop syndromic quantitative PCR diagnostic tests covering diseases of all organisms and fields using SGDDS, through global collaboration.

Seegene is committed to sharing its unique syndromic quantitative PCR technologies with leading companies around the world to collaborate with consortium partners to develop, manufacture and distribute diagnostic tests. The SG OneSystemTM hopes to alleviate the workload for a single company to develop products that cover all diseases including not only development, but also regulatory affairs, manufacturing, marketing and sales. The success of the SG OneSystemTM is that it will offer a comprehensive preventive measure that will contribute to a sustainable future for the entire biological ecosystem.

As part of the SG OneSystemTM business, Seegene in September 2023 launched the inaugural 'Open Innovation Program powered by Seegene' with Springer Nature to train experts, scientists and clinicians in the development of syndromic quantitative PCR assays in all application fields.

Photo -

Logo -

View original content: